First Wave BioPharma, Inc. (FWBI) Stock Analysis

First Wave BioPharma, Inc. (FWBI) Healthcare & Pipeline Overview

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company specializing in gastrointestinal disease therapies, utilizing niclosamide and adrulipase. With a focus on non-systemic treatments, the company targets conditions like ulcerative proctitis and exocrine pancreatic insufficiency, operating within the competitive biotechnology sector and facing typical development risks.

What Is the Investment Thesis for FWBI?

First Wave BioPharma, Inc. presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The company's focus on gastrointestinal diseases offers potential in a market with unmet needs. Key value drivers include the successful advancement of its pipeline assets, particularly niclosamide and adrulipase, through clinical trials. Positive Phase II results for FW-COV and FW-UP could serve as significant catalysts. However, the company's negative P/E ratio of -0.23 and a substantial negative profit margin of -16338.8% highlight the financial risks. The company's small size, with only 9 employees, also introduces operational risks. Investment hinges on the successful navigation of regulatory hurdles and securing additional funding to support ongoing clinical trials.

Based on FMP financials and quantitative analysis

FWBI Key Highlights

Market Cap of $5.99M reflects its status as a micro-cap company.

• P/E Ratio of -0.23 indicates the company is currently unprofitable.
• Profit Margin of -16338.8% highlights significant losses relative to revenue.
• Gross Margin of 50.0% suggests potential profitability if operating expenses are managed effectively.
• Beta of 1.28 indicates the stock is more volatile than the market.

Who Are FWBI's Competitors?

FWBI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FWBI's Key Strengths?

Pipeline of targeted therapies for gastrointestinal diseases.

• Focus on non-systemic treatments to minimize side effects.
• Proprietary drug formulations and patented technologies.
• Experienced management team with expertise in drug development.

What Are FWBI's Weaknesses?

Limited financial resources and reliance on external funding.

• High risk of clinical trial failures.
• Small size and limited infrastructure.
• Dependence on a small number of product candidates.

What Could Drive FWBI Stock Higher?

Phase II clinical trial results for FW-COV in treating COVID-19-related GI infections.

• Phase II clinical trial results for FW-UP in treating ulcerative proctitis and ulcerative proctosigmoiditis.
• Enrollment and progress in Phase Ib/IIa clinical trials for FW-UC.
• Development and potential partnering of Adrulipase for exocrine pancreatic insufficiency.

What Are the Key Risks for FWBI?

Financial-distress signal — its Altman Z-Score of -6.46 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to secure additional funding to support ongoing clinical trials.
• Unfavorable clinical trial outcomes for key product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from larger pharmaceutical companies with greater resources.
• Dependence on a small number of product candidates.

What Are the Growth Opportunities for FWBI?

• Advancement of FW-COV for COVID-19-related GI Infections: The ongoing Phase II clinical trials for FW-COV represent a significant growth opportunity. If successful, this could address the unmet need for treating gastrointestinal infections caused by SARS-CoV-2, potentially tapping into a market that emerged rapidly. Positive trial results could lead to partnerships or further funding, driving shareholder value. The timeline for potential commercialization depends on trial outcomes and regulatory approvals, but could be within the next 2-3 years.
• Development of FW-UP for Ulcerative Proctitis/Proctosigmoiditis: The Phase II clinical trials for FW-UP targeting ulcerative proctitis and ulcerative proctosigmoiditis represent a key growth area. Success in these trials could lead to a valuable treatment option for patients with these conditions. The market for ulcerative colitis treatments is substantial, and a successful non-systemic therapy could capture a significant share. Timeline for potential market entry is dependent on trial results and regulatory approvals.
• Expansion of Adrulipase for Exocrine Pancreatic Insufficiency: Adrulipase, targeting exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis, offers a distinct growth opportunity. This oral, non-systemic biologic capsule aims to improve fat digestion, addressing a critical need for these patients. Positive clinical data and subsequent regulatory approval could establish First Wave BioPharma as a key player in this niche market. Commercialization could be possible within 3-5 years pending successful trials and approvals.
• Progress of FW-ICI-AC for Immune Checkpoint Inhibitor-Associated Colitis and Diarrhea: The development of FW-ICI-AC to treat immune checkpoint inhibitor-associated colitis and diarrhea in advanced-stage oncology patients presents a targeted growth opportunity. As immune checkpoint inhibitors become more prevalent in cancer treatment, managing their side effects becomes increasingly important. A successful therapy in this area could provide significant relief to patients and generate revenue for the company. Clinical trials and regulatory approvals will dictate the timeline for market entry.
• Potential Partnerships and Licensing Agreements: First Wave BioPharma can pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of its pipeline assets. Collaborating with larger pharmaceutical companies or specialized biotech firms could provide access to additional funding, expertise, and market reach. These partnerships can de-risk the development process and enhance the company's ability to bring its therapies to market effectively. The timing and success of these partnerships are contingent on the progress of clinical trials and the attractiveness of the company's assets.

What Are FWBI's Competitive Advantages?

• Proprietary drug formulations and patented technologies.
• Clinical data supporting the safety and efficacy of its therapies.
• Expertise in developing non-systemic treatments for gastrointestinal diseases.
• Focus on niche markets with unmet needs, such as exocrine pancreatic insufficiency in cystic fibrosis patients.

What Does FWBI Do?

First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., was founded in 2014 and rebranded in September 2021. Headquartered in Boca Raton, Florida, the company is dedicated to the research and development of targeted and non-systemic therapies for gastrointestinal diseases. Their core focus is on developing treatments that address unmet needs in conditions like ulcerative proctitis, Crohn's disease, and exocrine pancreatic insufficiency. The company's lead product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and adrulipase, a recombinant lipase enzyme designed to improve fat digestion. First Wave BioPharma's pipeline includes FW-COV, currently in Phase II clinical trials for treating severe acute respiratory syndrome coronavirus 2 gastrointestinal infections. Other key programs include FW-UP, also in Phase II trials for ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced-stage oncology patients; and FW-UC, in Phase Ib/IIa clinical trials for ulcerative proctitis and ulcerative proctosigmoiditis. Additionally, FW-CD has completed Phase I clinical trials for Crohn's disease. Adrulipase, an oral, non-systemic biologic capsule, is being developed for exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company aims to provide innovative solutions for patients suffering from gastrointestinal disorders through targeted drug development.

What Products and Services Does FWBI Offer?

• Researches and develops targeted therapies for gastrointestinal diseases.
• Develops non-systemic treatments to minimize side effects.
• Focuses on oral small molecule and biologic therapies.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Targets conditions like ulcerative proctitis, Crohn's disease, and exocrine pancreatic insufficiency.
• Seeks regulatory approvals from agencies like the FDA for its therapies.
• Aims to provide innovative solutions for patients with unmet needs in gastrointestinal health.

How Does FWBI Make Money?

• Develops and patents novel therapeutic candidates for gastrointestinal diseases.
• Conducts preclinical and clinical trials to demonstrate safety and efficacy.
• Seeks partnerships or out-licensing agreements with larger pharmaceutical companies for commercialization.
• May manufacture and market products directly, pending regulatory approval and funding.

What Industry Does FWBI Operate In?

First Wave BioPharma operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. The market for gastrointestinal disease therapies is substantial, driven by the increasing prevalence of conditions like ulcerative colitis, Crohn's disease, and exocrine pancreatic insufficiency. The company competes with both large pharmaceutical companies and smaller biotech firms developing novel treatments for these conditions. Key trends include the development of targeted therapies and non-systemic treatments to minimize side effects. Companies like APTO, FRTX, GBNH, GMDA, and NBRVF also operate in the biotechnology space.

Who Are FWBI's Key Customers?

• Patients suffering from gastrointestinal diseases such as ulcerative proctitis, Crohn's disease, and exocrine pancreatic insufficiency.
• Hospitals and clinics that treat patients with these conditions.
• Pharmaceutical companies that may license or acquire First Wave BioPharma's therapies.
• Healthcare providers who prescribe medications for gastrointestinal disorders.

Company Profile

First Wave BioPharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boca Raton, US. The company is led by CEO James R. Sapirstein. FWBI has traded publicly since 2016.

First Wave BioPharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.46 places it in the distress zone, a signal of elevated financial risk.

Return on equity for First Wave BioPharma, Inc. stands at -18.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -42.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -41.6%, the inverse of the P/E and a quick read on earnings relative to price.

FWBI Valuation & Market Position

With a $5.99M market cap, First Wave BioPharma, Inc. sits in the micro-cap segment of the market.

Wall Street analysts project First Wave BioPharma, Inc. revenue of about $22.3M for fiscal 2026, with EPS near $-2.25.

The most recent 10 insider filings for First Wave BioPharma, Inc. break down as 5 sales and 5 purchases. On net that is roughly 71K shares acquired (about $27K) — insiders putting money in tends to read as conviction.

FWBI Financials

FWBI Latest News

No recent news available for FWBI.

Common Questions About FWBI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources